The research agreement with a reputable institution like the University of Virginia is likely to be viewed positively by investors as it may enhance the credibility of Xenetic Biosciences' platform and could accelerate the development timeline. This news may increase investor confidence in the company's research capabilities and potential for future growth, leading to a positive short term impact on the stock price.